FDA Promises Quicker Action, More Transparency in Misconduct Actions

The U.S. Food and Drug Administration (FDA) just announced it has enhanced it efforts to prevent noncompliant investigators and others from participating in new <"http://www.yourlawyer.com/practice_areas/defective_drugs">drug and <"http://www.yourlawyer.com/practice_areas/defective_medical_devices">medical device development. The FDA’s procedures for debarment and disqualification have been improved to better protect those participating in clinical studies and, also, for ensuring the safety and efficacy of the medical products marketed to the American public.

The agency explained that compliance with its statutes and regulations is key to protecting clinical study participants and the general public. The new debarment and disqualification procedures will also help ensure that sponsors of clinical studies do not unknowingly use individuals who potentially may be debarred or disqualified by the FDA.

“The FDA views any deviation from its high standards for developing or marketing drugs and devices as a potential threat to patient safety and public health,” said Norris Alderson, the FDA’s associate commissioner for science. “We will take strong action against anyone who chooses to ignore or flout the legal requirements for the products we regulate.”

Under current law, the FDA can ban, or debar, individuals known to have broken the law from working for companies with approved or pending drug applications at the FDA. The agency can also disqualify researchers conducting clinical testing of new drugs and devices, when the FDA determines that they have not followed the rules intended to protect study subjects. Further, the FDA can disqualify a clinical investigator who has, for example, manipulated data so as to inaccurately report study findings.

Some members of Congress have expressed concern that the FDA has not adequately used its debarment and disqualification authorities. Congress has also noted that when these authorities are invoked, the agency is slow to remove such individuals from the drug or device development process. Members of the House Energy and Commerce Committee have asked the Government Accountability Office (GAO) to examine the FDA’s debarment and disqualification procedures.

The FDA conducted a similar review of its processes and concluded that the agency should enhance its procedures to ensure it can act quickly, when needed, to further safeguard clinical trial subjects and the drug and device development processes. The revamped debarment and disqualification procedures, which include increased staffing and centralized coordination, ensure that more rapid, transparent, and consistent actions are taken. Since the measures have been in effect, debarment action rates have risen and action time has reduced, said the agency. The agency has also taken steps to ensure that sponsors involved in the testing and development of new medical products have ready access to information about FDA’s debarment and disqualification actions.

Under the previous administration, the agency was long accused of being corrupt and for a wide variety of issues, conflicts, and failures.

This entry was posted in Defective Medical Devices, Pharmaceuticals. Bookmark the permalink.

© 2005-2019 Parker Waichman LLP ®. All Rights Reserved.